DETAK by Brawijaya University Researchers detects Heart Disease Early and Accurately

Malang, East Java, Indonesia, Nov 27, 2020 – (ACN Newswire) – Researchers from the Brawijaya University (UB) Medical School in Malang, East Java have developed DETAK, a smartphone application for patients with heart disease. The app works on an AI (artificial intelligence) algorithm, to provide early and accurate detection of heart disease, or acute coronary syndrome, and prevent delays in proper diagnose and treatment.

Acute coronary syndrome describes a host of conditions linked to the sudden, reduced flow of blood to the heart. One such condition is a myocardial infarction, or heart attack, in which cell death results and can lead to damaged or destroyed heart tissue. DETAK was designed to prevent these types of occurrences with early discovery.

“Apart from functioning as an early detection tool encouraging patients to seek treatment, DETAK serves to remind heart disease patients to take their medication and undergo medical checkups regularly,” noted Mohammad

Read More

First Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease

— TED Today, a daily, online video series shares motivational stories from the TED community and useful resources to help people along their TED journey —

Today marks the start of the first-ever Thyroid Eye Disease (TED) Awareness Week, taking place from Nov. 16 to Nov. 20, to increase awareness of TED – a serious, progressive, and vision-threatening rare autoimmune disease. TED Awareness Week has been established through a collaboration among Horizon Therapeutics and advocacy organizations including the American Autoimmune Related Diseases Association (AARDA), the Alliance for Eye and Vision Research (AEVR), the Graves’ Disease and Thyroid Foundation (GDATF), and Prevent Blindness. Each organization is committed to the TED community and has a variety of activities planned, including the sharing of educational information and resources throughout the week.

While TED most commonly occurs in people with Graves’ disease, it is a separate disease that can occur without the presence of

Read More

Twist Bioscience Expands Infectious Disease Product Line Adding Comprehensive Viral Panel

— Panel Distinguishes Between More than 3,000 Different infectious Diseases —

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of the Twist Comprehensive Viral Research Panel, a next-generation sequencing (NGS) panel that includes more than 3,000 viral genomes to enable identification of new and divergent viral species in a single sample. The panel will be bundled with an analysis platform from One Codex to enable an easy-to-use, complete end-to-end workflow that begins from the Twist library preparation and target enrichment panel and continues through publication-ready visualizations.

“With a renewed focus on public health and the impact of viral identification and containment, we are launching the Twist Comprehensive Viral Research Panel for researchers globally,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We do not know when the next pandemic

Read More

Beam Therapeutics Presents First Data Highlighting Base Editing Program for Glycogen Storage Disease Type Ia at AASLD

Novel Base Editors for Two Most Common GSDIa Mutations Demonstrate Significantly Higher Levels of In Vivo Mutation Correction than Required to Restore Glucose Homeostasis

Previously Presented Data from Alpha-1 Program to be Reviewed in Encore Presentation

CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present preclinical data from its liver-focused programs, including the first data highlighting its novel base-editing strategy for correcting disease-causing mutations underlying Glycogen Storage Disease Type Ia (GSDIa), during the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting Digital Experience being held virtually November 13-16, 2020.

GSDIa, also known as Von Gierke disease, is an inborn disorder of glucose metabolism caused by mutations in the G6PC gene that disrupt a key enzyme, Glucose-6- Phosphatase (G6Pase), which is involved in

Read More

ZebiAI Joins the EUbOPEN Consortium to Provide Tools to Unlock Disease Biology

Applying ZebiAI’s ML-driven discovery platform will contribute to the discovery of novel biology and further understanding of disease pathways

ZebiAI is pleased to announce its participation in the 66 million-euro EUbOPEN Consortium, which aims to develop high quality chemical tool compounds for 1,000 proteins (one third of the druggable proteins in the human body). “Enabling and Unlocking biology in the OPEN” (EUbOPEN) is a recently launched public-private partnership empowering academia and industry alike to explore disease biology and unlock the discovery of new drug targets and treatments. ZebiAI joins 22 other partner organizations, including universities, research institutes, and large pharmaceutical companies.

ZebiAI’s Chemome Initiative, which utilizes a machine learning (ML)-driven discovery platform to further characterize the function of understudied proteins and validate novel therapeutic targets in partnership with the research community, is an ideal fit for EUbOPEN. ZebiAI’s platform utilizes vast datasets of high-quality protein-small molecule interaction data and proprietary

Read More

American Kidney Fund Announces Partnership with Tricida to Expand Education of Metabolic Acidosis in Patients with Kidney Disease

Press release content from Accesswire. The AP news staff was not involved in its creation.

ROCKVILLE, MD / ACCESSWIRE / October 22, 2020 / The American Kidney Fund (AKF) today announced a partnership with Tricida, Inc. to increase the understanding of chronic metabolic acidosis, a common complication of kidney disease that can cause serious effects, such as chronic kidney disease (CKD) progression, muscle atrophy and cardiac issues. Tricida’s support will allow AKF to develop and disseminate educational information about metabolic acidosis’ role in the progression of CKD.

“Complications of CKD, such as metabolic acidosis, create serious health problems, including patients’ kidney disease getting worse,” said LaVarne A. Burton, AKF president and CEO. “We are extraordinarily grateful to Tricida for its partnership in working with us to encourage patients to take metabolic acidosis management seriously.”

“Tricida is honored to partner with the American Kidney Fund on this

Read More

Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences

COPENHAGEN, Denmark, Oct. 21, 2020 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced five presentations featuring the company’s endocrinology rare disease programs at two upcoming medical conferences: European Calcified Tissue Society (ECTS) 2020, taking place online October 22–24, 2020, and the Pediatric Endocrinology Nursing Society (PENS) national conference, taking place online November 2–5, 2020.

During ECTS, results from the phase 2 PaTH Forward Trial of TransCon PTH in adult hypoparathyroidism (HP) will be presented. During PENS, data from the phase 3 fliGHt Trial of TransCon hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD) and from two clinical trials of the auto-injector for lonapegsomatropin. Additionally, the company will present posters highlighting the impact of achondroplasia (ACH) on the quality of life in children and their parents, which will help inform the TransCon CNP program.


Read More